5th Induced Proximity-Based Drug Discovery Summit

The rapid therapeutic success of PROTACs and Molecular Glue Degraders has underpinned a surge in new proximity-based modalities with the ability to treat a wide array of previously undruggable diseases. Last year alone there was a 72% increase in the number of induced proximity assets on Beacon by Hanson Wade.

Additionally, with significant funding - from a $186 million partnership between Photys Tx and Novo Nordisk, to the launch of new companies such as General Proximity and Outrun – the induced proximity field is experiencing unprecedented momentum, accelerating the next wave of novel drugs through discovery and translational pipeline for clinical validation.

Speakers: Aaron Frank, Director, Head of Computational and Chemistry, Arrakis Therapeutics, Abhishek Dogra, Director, Medicinal Chemistry and Induced Proximity, A-Alpha Bio, Arpita Sen, Scientist, Biochemistry, A-Alpha Bio, Benjamin Levin, Principal Scientist, Stablix, Craig Blain, Senior Director, RNA Biology, Arrakis Therapeutics, Eric Wang, Professor, Sanford Burnham Prebys Medical Discovery Institute, Hai Rao, Professor, Southern University of Science and Technology, James Mousseau, Director, Chemistry Halda Therapeutics, Jeff Warrington, Principal Scientist, Computational Drug Discovery | Digital Science and Innovation Novo Nordisk, Jun Qi, Associate Professor, Medicine Research Dana-Farber Harvard Cancer Center, Markus Haeberlein, EVP, Discovery Science Parabilis Medicines, Moses Moustakim, Senior Scientist, Chemistry Photys Therapeutics, Peggy Thompson, Vice President and Head of Biology Plexium, Richard Bonneau, Vice President, Drug Discovery, gRED Computational Sciences Genentech, Satoshi Konagai, Investment Lead Astellas Pharma, Seth Carbonneau Senior Principal Scientist Novartis, Sriram Subramaniam, CEO and Founder Gandeeva Therapeutics, Tyzoon Nomanbhoy, Vice President, Chemical Biology Vicinitas Therapeutics